Literature DB >> 18046419

Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes.

N Perico1, G Remuzzi.   

Abstract

Actual strategies to delay progression of diabetic nephropathy provide imperfect protection when started late in the course of the disease. Ohtomo et al. now demonstrate that thiazolidinedione treatment was associated with a remarkable improvement in proteinuria and renal function, offering a new potential treatment for diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046419     DOI: 10.1038/sj.ki.5002654

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?

Authors:  Marcus D Säemann; Michael Krebs
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

2.  Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.

Authors:  Akizuki Morikawa; Kanaki Ishizeki; Yasunori Iwashima; Hiroki Yokoyama; Eiji Muto; Eiji Oshima; Masatomo Sekiguchi; Takanori Miura; Hiroshi Itoh; Masakazu Haneda
Journal:  Clin Exp Nephrol       Date:  2011-08-09       Impact factor: 2.801

Review 3.  Diabetic nephropathy: a disorder of oxygen metabolism?

Authors:  Toshio Miyata; Charles van Ypersele de Strihou
Journal:  Nat Rev Nephrol       Date:  2009-12-15       Impact factor: 28.314

4.  High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes.

Authors:  Rui Mao; Fan Yang; Yu Zhang; Hongtao Liu; Pengsen Guo; Yanjun Liu; Tongtong Zhang
Journal:  Aging (Albany NY)       Date:  2021-03-11       Impact factor: 5.682

5.  Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.

Authors:  Mee Kyoung Kim; Seung-Hyun Ko; Ki-Hyun Baek; Yu-Bae Ahn; Kun-Ho Yoon; Moo-Il Kang; Kwang-Woo Lee; Ki-Ho Song
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 3.165

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.